CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses:
General and administrative (including stock-based compensation)	526,644	859,011	1,828,917	2,356,047
Depreciation	331	461	1,251	1,185
Research and development (including stock-based compensation)	6,144	24,242	21,873	67,833
Total operating expenses	533,119	883,714	1,852,041	2,425,065
Loss from operations	(533,119)	(883,714)	(1,852,041)	(2,425,065)
Other (income) expense:
Interest income	(107)	(1,342)	(611)	(4,652)
Gain (loss) on disposal of assets	972	0	972	0
Interest expense	(4,161)	24,488	(149,879)	(86,892)
Total other expense	5,026	(25,830)	150,240	82,240
Net income (loss)	(538,145)	(857,884)	(2,002,281)	(2,507,305)
Net loss attributable to the noncontrolling interest	0	0	0	0
Net income (loss) applicable to Bion's common stockholders	$ (538,145)	$ (857,884)	$ (2,002,281)	$ (2,507,305)
Net income (loss) applicable to Bion's common stockholders per basic common share	$ (0.01)	$ (0.02)	$ (0.04)	$ (0.06)
Net income (loss) applicable to Bion's common stockholders per diluted common share	$ (0.01)	$ (0.02)	$ (0.04)	$ (0.06)
Weighted-average number of common shares outstanding, Basic	54,035,865	45,456,417	50,498,173	44,165,309
Weighted-average number of common shares outstanding, Diluted	54,035,865	45,456,417	50,498,173	44,165,309